195 related articles for article (PubMed ID: 29475597)
1. [Autoimmune hypophysitis associated with new anti-cancer immunotherapies].
Jannin A; Merlen E; Do Cao C; Penel N
Bull Cancer; 2018 Mar; 105(3):275-280. PubMed ID: 29475597
[TBL] [Abstract][Full Text] [Related]
2. [Checkpoint inhibitors-induced hypophysitis].
du Payrat JA; Cugnet-Anceau C; Maillet D; Levy M; Raverot G; Disse E; Borson-Chazot F
Bull Cancer; 2020 Apr; 107(4):490-498. PubMed ID: 32200950
[TBL] [Abstract][Full Text] [Related]
3. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
5. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
6. Hypophysitis in 2014.
Allix I; Rohmer V
Ann Endocrinol (Paris); 2015 Oct; 76(5):585-94. PubMed ID: 26514950
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
Faje A
Pituitary; 2016 Feb; 19(1):82-92. PubMed ID: 26186958
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
9. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.
Zhao Y; Yang W; Huang Y; Cui R; Li X; Li B
Cell Physiol Biochem; 2018; 47(2):721-734. PubMed ID: 29794465
[TBL] [Abstract][Full Text] [Related]
10. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
12. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy.
Mekki A; Dercle L; Lichtenstein P; Nasser G; Marabelle A; Champiat S; Chouzenoux E; Balleyguier C; Ammari S
Eur J Cancer; 2019 Sep; 119():44-56. PubMed ID: 31415986
[TBL] [Abstract][Full Text] [Related]
13. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Deligiorgi MV; Liapi C; Trafalis DT
Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
15. Endocrine dysfunction following immune checkpoint inhibitor therapy.
Konda B; Nabhan F; Shah MH
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up.
Levy M; Abeillon J; Dalle S; Assaad S; Borson-Chazot F; Disse E; Raverot G; Cugnet-Anceau C
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33066179
[TBL] [Abstract][Full Text] [Related]
17. To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
Pantuck M; McDermott D; Drakaki A
Cancer; 2019 Oct; 125(20):3506-3513. PubMed ID: 31318445
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
20. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
